<DOC>
	<DOCNO>NCT00897806</DOCNO>
	<brief_summary>RATIONALE : DNA analysis tumor tissue patient cancer may help doctor predict patient respond treatment plan best treatment . PURPOSE : This laboratory study identify genetic marker predict response paclitaxel patient newly diagnose stage III stage IV ovarian epithelial cancer primary peritoneal cancer .</brief_summary>
	<brief_title>Identifying Genetic Markers That Predict Response Paclitaxel Patients With Newly Diagnosed Stage III Stage IV Ovarian Epithelial Cancer Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Identify genetic marker paclitaxel chemosensitivity and/or chemoresistance , use gene expression array , patient newly diagnose stage III IV ovarian epithelial cancer primary peritoneal cancer treat single-agent weekly paclitaxel follow paclitaxel combination carboplatin . - Correlate RNA expression level clinical response patient treat regimen . Secondary - Determine response rate patient treat regimen . - Determine progression-free survival overall survival patient treat regimen . - Compare transcriptional profile primary tumor vs tissue obtain second-look surgery patient treat regimen . - Identify differential expression pre- post-treatment tissue patient treat regimen . OUTLINE : This pilot study . Pre- post-chemotherapy tumor sample undergo transcriptional profiling use cDNA microarrays identify gene overexpression . The gene expression profile paclitaxel-sensitive tumor compare paclitaxel resistant identify gene marker associate response paclitaxel . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . Patients newly diagnose histologically confirm advanced stage ( III &amp; IV ) epithelial ovarian cancer , fallopian tube peritoneal cancer . OR Patients suspected malignancy unsuitable candidate surgery ( i.e. , medical comorbidities , massive effusion , tumor burden optimal resection unlikely ) undergo core biopsy positive malignancy . 2 . Patients undergone tumor reduction must either stage III suboptimal ( &gt; 2 cm residual ) disease stage IV disease . 3 . Patients may prior chemotherapeutic regimen . 4 . Zubrod performance status 0 , 1 , 2 . 5 . Patients must recover effect recent surgery . They free significant infection . 6 . Patients must adequate : Bone marrow function : WBC &gt; /= 3,000/microlitre , platelet &gt; 100,000/microlitre , absolute neutrophil ( ANC ) count &gt; /= 1.5/microlitre . Renal function : Creatinine &lt; /= 1.5 mg % . Hepatic function : Bilirubin &lt; /= 1.5 mg/dl , SGOT alkaline phosphatase &lt; /= 3 X institutional normal . 7 . Patients must adequate : Neurologic function : Preexisting peripheral neurologic toxicity allow limited parasthesia decrease vibratory sense without motor weakness . Intermittent constipation manage laxative allow , without evidence bowel obstruction . Psychiatric function : Functions independently without evidence delirium , confusion , suicidal ideation , untreated depression . 8 . Patients sign approve informed consent . 1 . Patients borderline grade 1 ( low grade ) tumor . 2 . Patients receive prior cytotoxic chemotherapy radiotherapy . 3 . Patients septicemia , severe infection , acute hepatitis , gastrointestinal bleeding time protocol entry . 4 . Patients unstable angina myocardial infarction within past six month . Patients evidence abnormal cardiac conduction ( e.g. , bundle branch block , heart block , etc . ) eligible disease stable past six month . 5 . Patients whose circumstance permit completion study require followup . 6 . Patients history another malignancy within 5 year . Patients prior malignancy remain continuously free recurrent persistent disease 5 year may enter study consultation study chair . 7 . Patients significant preexisting cardiac disease ( NYHA class IIIIV ) exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
</DOC>